Drug intelligence / Profile preview

ligilactobacillus salivarius DSM 34078

Development stage: Unknown
Lead developer: Novonesis
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Ligilactobacillus salivarius DSM 34078 is a specific strain of lactic acid bacteria (LAB) that functions as a probiotic. It is commonly found in the oropharyngeal-gastrointestinal tract and is recognized for its various health-promoting properties. Its mechanism of action involves modulating the gut microbiota by increasing beneficial bacteria and reducing harmful ones, regulating immune responses by enhancing anti-inflammatory pathways and reducing pro-inflammatory cytokines, producing antimicrobial compounds like bacteriocins and lactic acid, and strengthening the gut barrier function. This strain has also demonstrated antioxidant activity. It has been investigated for its potential therapeutic benefits in conditions such as lactose intolerance, irritable bowel syndrome, pancreatic necrosis, atopic dermatitis, and oral health.

Other names: Lactobacillus salivarius DSM 34078

Beyond the preview

Go deeper on ligilactobacillus salivarius DSM 34078.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ligilactobacillus salivarius DSM 34078.

Explore the full profile